Cellectis (CLLS) Non-Current Debt (2014 - 2026)
Cellectis (CLLS) recorded quarterly Non-Current Debt of $67.5 million in Q1 2026, down 8.8% quarter-over-quarter from $74.0 million in Q4 2025, and up 32.25% on a YoY basis from $51.0 million in Q1 2025.
Cellectis (CLLS) Non-Current Debt (2014 - 2026) Analysis & Trends
Cellectis' Non-Current Debt history runs 12 years deep, the most recent figure standing at $67.5 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 32.25% year-over-year to $67.5 million; the TTM figure through Mar 2026 stood at $67.5 million (up 32.25% YoY), while the FY2025 annual figure was $74.0 million, up 45.46% from the prior year.
- Non-Current Debt was $67.5 million for Q1 2026 at Cellectis, down from $74.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $74.0 million in Q4 2025 to a low of $14.7 million in Q3 2022.
- Historically, Non-Current Debt has averaged $45.1 million across 5 years, with a median of $50.9 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt slumped 35.44% in 2022, then surged 219.07% in 2024.
- A 5-year view of Non-Current Debt shows it stood at $20.5 million in 2022, then jumped by 139.27% to $49.1 million in 2023, then increased by 3.58% to $50.9 million in 2024, then soared by 45.46% to $74.0 million in 2025, then decreased by 8.8% to $67.5 million in 2026.
- The last three Non-Current Debt figures came in at $67.5 million (Q1 2026), $74.0 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 67.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.50 Mn |
| Mar 31, 2026 | 67.50 Mn |
| Dec 31, 2025 | 74.01 Mn |
| Dec 31, 2025 | 74.01 Mn |
| Sep 30, 2025 | 63.40 Mn |
| Sep 30, 2025 | 63.40 Mn |
| Jun 30, 2025 | 55.86 Mn |
| Jun 30, 2025 | 55.86 Mn |
| Mar 31, 2025 | 51.04 Mn |
| Mar 31, 2025 | 51.04 Mn |
| Dec 31, 2024 | 50.88 Mn |
| Dec 31, 2024 | 50.88 Mn |
| Sep 30, 2024 | 61.58 Mn |
| Sep 30, 2024 | 61.58 Mn |
| Jun 30, 2024 | 58.35 Mn |
| Jun 30, 2024 | 58.35 Mn |
| Mar 31, 2024 | 62.62 Mn |
| Mar 31, 2024 | 62.62 Mn |
| Dec 31, 2023 | 49.13 Mn |
| Dec 31, 2023 | 49.13 Mn |